1,484 results on '"Sciot, Raf"'
Search Results
2. A novel methylation signature predicts extreme long-term survival in glioblastoma
3. Extensive surgical resections for rare pleural neoplasms: a single-center experience with a yolk sac tumor and synovial sarcoma
4. High Resolution Mass Spectrometry of Cystine-Containing Neuropeptides in Histological Sections of Human FFPE Tissue Banks
5. Potentially actionable targets in synovial sarcoma: A tissue microarray study
6. EWSR1::POU2AF3(COLCA2) Sarcoma: An Aggressive, Polyphenotypic Sarcoma With a Head and Neck Predilection
7. Molecular characterization of an embryonal rhabdomyosarcoma occurring in a patient with Kabuki syndrome: report and literature review in the light of tumor predisposition syndromes
8. Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma
9. Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour
10. Generation of patient-derived models from a metastatic pediatric diffuse leptomeningeal glioneuronal tumor with KIAA1549::BRAF fusion
11. Medial cutaneous nerve neuroma-in-continuity within the ulnar nerve: a report of 2 cases
12. Towards real-time intraoperative tissue interrogation for REIMS-guided glioma surgery
13. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.
14. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
15. Vascular Tumors
16. Skeletal Muscle Tumors
17. Adipocytic Tumors
18. YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases
19. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE
20. Encephalocraniocutaneous lipomatosis phenotype associated with mosaic biallelic pathogenic variants in the NF1 gene.
21. Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors
22. Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study
23. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization
24. Detailed histological analysis of a thrombectomy-resistant ischemic stroke thrombus: a case report
25. Next generation sequencing for GNAS uncovers CD34 as a sensitive marker for intramuscular myxoma
26. Spatial single-cell profiling of deeply matched extreme long-term surviving glioblastoma patients reveals a distinct immune and stem cell driven ecosystem
27. Myopericytoma in an Infant—Imaging Characteristics of a Rare but Benign Entity
28. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
29. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’
30. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors
31. Case report: Cardiac intimal sarcoma in a young child
32. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial
33. Neural Fibrolipoma
34. Intramuscular Hemangioma
35. Neurofibroma (All Variants)
36. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
37. Nodular Fasciitis
38. Solitary Circumscribed Neuroma
39. Pseudosarcomatous Myofibroblastic Proliferations
40. Rhabdomyosarcoma of the Adult Prostate: Two Cases With Molecular and Cytogenetic Analyses
41. Evidence of amyloid-β cerebral amyloid angiopathy transmission through neurosurgery
42. Supplementary Fig. 6 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
43. Supplementary Fig. 3 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
44. Supplementary Fig. 4 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
45. Supplementary Tables 1 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
46. Supplementary Fig. 1 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
47. Data from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
48. Supplementary Fig. 5 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
49. Supplementary Fig. 2 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
50. The Filum Terminale: A Cadaver Study of Anatomy, Histology, and Elastic Properties
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.